Via Surgical

Company Overview

Snapshot

Founded in March 2012 by Arik Levy, Via Surgical operates with 1–10 employees. The company has raised $8.15M across 4 funding rounds from 4 investors. In March 2021, Via Surgical received an investment from Catcher Technology.

Business overview

Via Surgical develops the FasTouch system, a transfascial suture fixation solution for hernia repair. The core technology utilizes lightweight, deployable sutures with a closed, locked-loop concept to provide strong and consistent fixation, aiming to reduce foreign body response and chronic pain. The company serves the medical devices industry, specifically focusing on surgical instruments and soft tissue repair within the Health Tech & Life Sciences sector.

Strategic signal

In October 2023, Via Surgical ceased operations. This indicates a significant and definitive shift in the company's trajectory, signaling to investors and innovation teams that the venture is no longer active in the market.

Company Intelligence Q&A

What is the primary product developed by Via Surgical?

Via Surgical developed the FasTouch system, designed for transfascial suture fixation in hernia repair, featuring lightweight, deployable sutures with a closed, locked-loop concept.

When did Via Surgical cease operations?

Via Surgical ceased to operate in October 2023, marking the end of its activities in the medical device sector.

How many FDA clearances has Via Surgical received?

Via Surgical has received three FDA clearances for its medical devices, including one for its FasTouch Absorbable Fixation System in March 2019 and another for the TissueTak Tendon Anchor in June 2021.

What recognition did Via Surgical receive for its soft tissue fixation system?

Via Surgical's soft tissue fixation system was voted one of the Top 10 Surgical Solutions by MedTech Outlook Review.